Patrick Lamy - 30 Jun 2025 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Reporting relationship: Senior VP, Commercial Strategy
Issuer ticker: AKRO
Reported as of: 30 Jun 2025
Net transaction value: +$4,607
SEC form: 4
Accepted by SEC: 02 Jul 2025, 18:00:19 UTC
Prior SEC filing: 20 Jun 2025
Next SEC filing: 03 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Jonathan Young, Attorney-in-Fact

Key filing fact

Patrick Lamy filed Form 4 for Akero Therapeutics, Inc. (AKRO) on 02 Jul 2025.

Key facts

This page summarizes Patrick Lamy's Form 4 filing for Akero Therapeutics, Inc. (AKRO).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 02 Jul 2025, 18:00.

Change

Previous filing in this sequence was filed on 20 Jun 2025.
Current net transaction value: +$4,607.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001961273 Primary reporting owner

Lamy Patrick

Relationship: Senior VP, Commercial Strategy
Address: C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BLVD, SUITE 350, SOUTH SAN FRANCISCO
Signature: /s/ Jonathan Young, Attorney-in-Fact
Signature date: 02 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AKRO transaction

Common Stock

Award

Transaction value: $4,607
Shares: +193
Change %: +0.61%
Price: $23.87
Shares after: 31,891
Date: 30 Jun 2025
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Mr. Lamy is voluntarily reporting the acquisition of these shares on June 30, 2025 pursuant to the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(c) and Rule 16b-3(d).

Footnote F2

In accordance with the provisions of the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan, these shares were purchased at 85% of the closing price of the Issuer's common stock on January 2, 2025.